Predictive Modeling of Novel Somatic Mutation Impacts on Cancer Prognosis: A Machine Learning Approach Using the COSMIC Database

preprint OA: closed
📄 Open PDF Full text JSON View at publisher

Abstract

Abstract Background Somatic mutations play a crucial role in cancer initiation, progression, and treatment response. While high-throughput sequencing has vastly expanded our understanding of cancer genomics, interpreting the functional impact of novel somatic mutations remains challenging. Machine learning approaches show promise in predicting mutation impacts, but robust models for accurate prognosis across different cancer types are still needed. Objective This study aimed to develop and validate a machine learning model using the Catalogue of Somatic Mutations in Cancer (COSMIC) database to predict the functional impact of novel somatic mutations on cancer prognosis across various cancer types. Methods We extracted data on 6,573,214 coding point mutations across 1,391 cancer types from COSMIC v95. We engineered 47 features for each mutation, including sequence context, protein domain information, evolutionary conservation scores, and frequency data. We developed and compared Random Forest, XGBoost, and Deep Neural Network models, selecting XGBoost based on performance. The model was evaluated using standard metrics and externally validated using data from The Cancer Genome Atlas (TCGA). Results The XGBoost model achieved an area under the Receiver Operating Characteristic curve (AUC-ROC) of 0.89 on the test set and 0.86 on the TCGA validation set. The model demonstrated consistent performance across major cancer types (AUC-ROC range: 0.85-0.92). Key predictive features included evolutionary conservation score, protein domain disruption, and mutation frequency. The model correctly identified 87% of known driver mutations and predicted 3,241 potentially high-impact novel mutations. Model predictions significantly correlated with patient survival in the TCGA dataset (HR = 1.8, 95% CI: 1.6-2.0, p < 0.001). Conclusions Our machine learning model shows strong predictive power in assessing the functional impact of somatic mutations on cancer prognosis across various cancer types. This approach has potential applications in research prioritization and clinical decision support, contributing to the advancement of precision oncology. Keywords cancer genomics; somatic mutations; machine learning; prognosis prediction; COSMIC database; precision oncology
Full text 3,986 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Background Somatic mutations play a crucial role in cancer initiation, progression, and treatment response. While high-throughput sequencing has vastly expanded our understanding of cancer genomics, interpreting the functional impact of novel somatic mutations remains challenging. Machine learning approaches show promise in predicting mutation impacts, but robust models for accurate prognosis across different cancer types are still needed.

Objective

This study aimed to develop and validate a machine learning model using the Catalogue of Somatic Mutations in Cancer (COSMIC) database to predict the functional impact of novel somatic mutations on cancer prognosis across various cancer types.

Methods

We extracted data on 6,573,214 coding point mutations across 1,391 cancer types from COSMIC v95. We engineered 47 features for each mutation, including sequence context, protein domain information, evolutionary conservation scores, and frequency data. We developed and compared Random Forest, XGBoost, and Deep Neural Network models, selecting XGBoost based on performance. The model was evaluated using standard metrics and externally validated using data from The Cancer Genome Atlas (TCGA).

Results

The XGBoost model achieved an area under the Receiver Operating Characteristic curve (AUC-ROC) of 0.89 on the test set and 0.86 on the TCGA validation set. The model demonstrated consistent performance across major cancer types (AUC-ROC range: 0.85-0.92). Key predictive features included evolutionary conservation score, protein domain disruption, and mutation frequency. The model correctly identified 87% of known driver mutations and predicted 3,241 potentially high-impact novel mutations. Model predictions significantly correlated with patient survival in the TCGA dataset (HR = 1.8, 95% CI: 1.6-2.0, p < 0.001).

Conclusions

Our machine learning model shows strong predictive power in assessing the functional impact of somatic mutations on cancer prognosis across various cancer types. This approach has potential applications in research prioritization and clinical decision support, contributing to the advancement of precision oncology. Competing Interest Statement The authors have declared no competing interest. Funding Statement This study did not receive any funding. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used ONLY openly available human data that were originally located at: The Catalogue of Somatic Mutations in Cancer (COSMIC) database (https://cancer.sanger.ac.uk/cosmic) The Cancer Genome Atlas (TCGA) (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the author.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00